PATENT CLAIM ANALYSIS

Application Number: 15952945
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "133100"]

Abstract:
The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

Claim (Index 61):
A method of removing an antigen from plasma, the method comprising:\n (a) identifying an individual in need of having an antigen removed from the individual's plasma; (b) administering an antibody to the individual wherein the antibody binds to the antigen through the antigen-binding domain of the antibody and has a KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KB for the antigen at pH 7.4, of 2 to 1,000, and wherein the antibody binds to the antigen in plasma in vivo and dissociates from the bound antigen under conditions present in an endosome in vivo, and wherein the antibody is a human IgG or a humanized IgG.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 91.0
- Lexical Diversity: 1.31818
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13889512', '13889484', '13595139', '14741786', '12680087']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.745558802087236
- 35 USC 102 Novelty (BERT): 0.7493612925435835
- Combined Prediction Score: 0.7459390511328707
- Mean Citation Score: 654.3324599999999
- Max Citation Score: 879.704
- Similarity Product: 807.7332156610487

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test